ACP
EPZM

Acuta Capital Partners’s Epizyme, Inc EPZM Stock Holding History

Acuta Capital Partners’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-140,000
Closed -$1.8M – 76
2015
Q3 		$1.8M Buy
+140,000
New +$2.83M 1.04% 33

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's EPZM Position: Q4 2015 in Review

Acuta Capital Partners sold out of Epizyme, Inc (EPZM) in Q4 2015, closing a stake of 140,000 shares — an estimated $1.8M sold.

Acuta Capital Partners first reported a position in EPZM in Q3 2015 and held it in 1 quarter. The position peaked at $1.8M in Q3 2015. 89 funds tracked by Wall St. Rank hold EPZM as of Q4 2015.

  • Acuta Capital Partners reported no remaining Epizyme, Inc position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 140,000 Epizyme, Inc shares in Q4 2015, an estimated $1.8M.
  • Acuta Capital Partners first reported a position in Epizyme, Inc in Q3 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Epizyme, Inc position peaked at $1.8M in Q3 2015.
  • 89 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.